ReviewFrontiers in pharmacology2021

Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Lei Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.